Evidence map›Paper›PMID 28251386›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2017

Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.

Kumar Kandadi Muralidharan, Deb Steiner, Diogo Amarante, Pei-Ran Ho, Dan Mikol, Jacob Elkins, Meena Subramanyam, Ivan Nestorov

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Kumar Kandadi MuralidharanSystems Pharmacology, Biogen, 14 Cambridge Center, Cambridge, MA, 02142, USA.
Deb SteinerClinical Development, Biogen, Cambridge, MA, USA.
Diogo AmaranteGlobal Medical Affairs, Biogen, Cambridge, MA, USA.
Pei-Ran HoGlobal Medical Affairs, Biogen, Cambridge, MA, USA.
Dan MikolClinical Development, Biogen, Cambridge, MA, USA.
Jacob ElkinsClinical Development, Biogen, Cambridge, MA, USA.
Meena SubramanyamGlobal Biomarker Discovery and Development, Biogen, Cambridge, MA, USA.
Ivan NestorovSystems Pharmacology, Biogen, 14 Cambridge Center, Cambridge, MA, 02142, USA. ivan.nestorov@biogen.com.
Biogen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natalizumab, a human immunoglobulin monoclonal antibody that targets α

Indexed as

AdolescentAdultAgedAntibodies, Monoclonal, HumanizedClinical Trials as TopicFemaleGadoliniumHumansMaleMiddle AgedMultiple SclerosisNatalizumabRecurrenceTreatment OutcomeYoung AdultAntibodies, Monoclonal, HumanizedGadoliniumNatalizumabAnnualized relapse rateGadolinium-enhancingMultiple sclerosisOnce-every-4-weeks dosing regimenPharmacokinetics

Identifiers

PMID28251386
OpenAlexW2594334857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.